Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02798536 · OUTCOME

Median Overall Survival (OS)

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma · Source last updated 2022-08-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
At death, up to 60.8 months

What was measured

OS is defined as the duration of time from start of treatment to time of death.

Groups in this outcome

Dose Level 1: 170mcg LMB-100

Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.

Dose Level -1: 140mcg LMB-100

Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.

Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel

Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1: 170mcg LMB-1003
Dose Level -1: 140mcg LMB-1007
Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel11

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose Level 1: 170mcg LMB-10033.5Not reported27.734.6Not reported
Dose Level -1: 140mcg LMB-10016.9Not reported6.860.8Not reported
Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel10.1Not reported3.730.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        27.7
        upper Limit
        34.6
        value
        33.5
      2. group Id
        OG001
        lower Limit
        6.8
        upper Limit
        60.8
        value
        16.9
      3. group Id
        OG002
        lower Limit
        3.7
        upper Limit
        30.9
        value
        10.1
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      7
    3. group Id
      OG002
      value
      11
    units
    Participants
description
OS is defined as the duration of time from start of treatment to time of death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.
    id
    OG000
    title
    Dose Level 1: 170mcg LMB-100
  2. description
    Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.
    id
    OG001
    title
    Dose Level -1: 140mcg LMB-100
  3. description
    Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.
    id
    OG002
    title
    Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel
param Type
MEDIAN
reporting Status
POSTED
time Frame
At death, up to 60.8 months
title
Median Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice